Antipsychotic

Antipsychotic drug use correlated to staffing levels

McKnight's Staff May 01, 2012

While antipsychotic drug use overuse has decreased since 2005, nearly a quarter of U.S. nursing homes are still giving many residents the medications against recommendations, a Boston Globe analysis reveals.

Federal prosecutors reject $1 billion J & J settlement

McKnight's Staff March 12, 2012

Government prosecutors rejected a proposed settlement worth roughly $1 billion with pharmaceutical giant Johnson & Johnson over questionable marketing tactics for the antipsychotic Risperdal.

Senate hearing on antipsychotic use in nursing homes to be held today

November 29, 2011

The Senate Special Committee on Aging will hold a hearing today about the use of antipsychotics in nursing homes.The hearing, titled "Overprescribed: The Human and Taxpayers' Costs of Antipsychotics in Nursing Homes," will be at 2 pm ET.

AstraZeneca settles for $520 million following investigation into improper marketing of anti-psychotic drug

April 28, 2010

Pharmaceutical giant AstraZeneca has agreed to pay $520 million to end a federal investigation into its alleged illegal marketing of the drug Seroquel for off-label uses, according to reports from Washington.

Department of Justice files suit against Johnson & Johnson in connection with kickback scheme with Omnicare

January 19, 2010

The U.S. Department of Justice on Friday filed a lawsuit against Johnson & Johnson for its alleged role in a kickback scheme with Omnicare, the nation's largest long-term care pharmacy chain.